Saby George
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Saby George has a total of 648 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Peter Petrylak
Smilow Cancer Center, Yale School of Medicine, New Haven, CT
40 shared publications - Evan Y. Yu
Fred Hutchinson Cancer Center 4 Clinical Research Division Seattle, Washington
40 shared publications - Alicia K. Morgans
Dana-Farber Cancer Institute, Boston, MA, USA
39 shared publications - Bernhard J. Eigl
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
39 shared publications - David D. Chism
Thompson Cancer Survival Center, Knoxville, USA
39 shared publications - Elisabeth I. Heath
Mayo Clinic Rochester Minnesota USA
39 shared publications
Latest Publications
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (11) , 1609-1617
Treatment Patterns and Costs Among Patients With Metastatic Renal Cell Carcinoma in the United States: A Real-World Study Using Integrated Claims and Clinical Data
PURPOSE: The treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved in recent years with the use of tyrosine kinase inhibitors (TKIs) and immuno-oncology (IO) therapies. This study examined patient characteristics, treatment patterns, health care resource utilization (HCRU), costs, and survival for individuals with mRCC who received either IO + IO or IO + TKI combinations as first-line (1L) regimens. METHODS: This retrospective cohort study used integrated claims and clinical data from a commercial health plan to study adults with mRCC who began 1L treatment between April 1, 2018, and January 31, 2023. Patient characteristics, 1L and second-line (2L) regimens, and HCRU were described. Costs were summarized per patient per month over time. Survival time was analyzed overall and partitioned into time on 1L, treatment-free survival, and survival after 2L. RESULTS: Patients receiving 1L IO + IO (n = 471) or IO + TKI (n = 353) regimens generally had similar baseline characteristics although among patients with risk data, 33% of IO-IO patients versus 23% of IO-TKI patients had poor risk scores. Treatment costs were higher for IO + IO in the first 3 months but lower in subsequent time intervals compared with IO + TKI. Total mean costs per patient were $720K in US dollars (USD) for IO + IO and $834K USD for IO + TKI over the course of 3 years. Medication costs represented 80% of total costs. IO + IO patients stayed on 1L therapy for a shorter duration, but cumulative survival time at 24 months was the same (63%) for both groups. CONCLUSION: Patients receiving 1L IO + IO and IO + TKI regimens had similar baseline characteristics and comparable survival at 30 months. Although IO + IO was associated with higher treatment costs in the first 3 months, the subsequent monthly costs were lower compared with IO + TKI.
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (11) , 1609-1617
Treatment Patterns and Costs Among Patients With Metastatic Renal Cell Carcinoma in the United States: A Real-World Study Using Integrated Claims and Clinical Data
PURPOSE: The treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved in recent years with the use of tyrosine kinase inhibitors (TKIs) and immuno-oncology (IO) therapies. This study examined patient characteristics, treatment patterns, health care resource utilization (HCRU), costs, and survival for individuals with mRCC who received either IO + IO or IO + TKI combinations as first-line (1L) regimens. METHODS: This retrospective cohort study used integrated claims and clinical data from a commercial health plan to study adults with mRCC who began 1L treatment between April 1, 2018, and January 31, 2023. Patient characteristics, 1L and second-line (2L) regimens, and HCRU were described. Costs were summarized per patient per month over time. Survival time was analyzed overall and partitioned into time on 1L, treatment-free survival, and survival after 2L. RESULTS: Patients receiving 1L IO + IO (n = 471) or IO + TKI (n = 353) regimens generally had similar baseline characteristics although among patients with risk data, 33% of IO-IO patients versus 23% of IO-TKI patients had poor risk scores. Treatment costs were higher for IO + IO in the first 3 months but lower in subsequent time intervals compared with IO + TKI. Total mean costs per patient were $720K in US dollars (USD) for IO + IO and $834K USD for IO + TKI over the course of 3 years. Medication costs represented 80% of total costs. IO + IO patients stayed on 1L therapy for a shorter duration, but cumulative survival time at 24 months was the same (63%) for both groups. CONCLUSION: Patients receiving 1L IO + IO and IO + TKI regimens had similar baseline characteristics and comparable survival at 30 months. Although IO + IO was associated with higher treatment costs in the first 3 months, the subsequent monthly costs were lower compared with IO + TKI.
- Open Access
- 14 June 2025
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 139, 102974
Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspective
- 14 June 2025
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 139, 102974
Open AccessSystematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspective
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S11. Statistical Assessment of Dose Proportionality for ADC, Power Model, PK Analysis Set
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S11. Statistical Assessment of Dose Proportionality for ADC, Power Model, PK Analysis Set
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S9. Serum PK Parameters of TAb at Cycle 1, Day 1, PK Analysis Set
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S9. Serum PK Parameters of TAb at Cycle 1, Day 1, PK Analysis Set
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S6. Serum PK Parameters of AGS15E ADC at Cycle 1, Day 15, PK Analysis Set
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S6. Serum PK Parameters of AGS15E ADC at Cycle 1, Day 15, PK Analysis Set
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S7. Serum PK Parameters of MMAE at Cycle 1, Day 1, PK Analysis Set
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S7. Serum PK Parameters of MMAE at Cycle 1, Day 1, PK Analysis Set
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S15 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S15. DCR With Confirmation; Parts A, B, and C, Expansion Phase
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S15 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S15. DCR With Confirmation; Parts A, B, and C, Expansion Phase
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S4. TEAEs (≥10% Patients) by SOC and PT: Part A, Escalation Phase
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S4. TEAEs (≥10% Patients) by SOC and PT: Part A, Escalation Phase
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S14 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S14. BOR, ORR, and DCR With Confirmation; Part A, Escalation Phase
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S14 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S14. BOR, ORR, and DCR With Confirmation; Part A, Escalation Phase
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S11. Statistical Assessment of Dose Proportionality for ADC, Power Model, PK Analysis Set
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S11. Statistical Assessment of Dose Proportionality for ADC, Power Model, PK Analysis Set